Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience

Abstract Ibrutinib is highly effective in patients with relapsed or refractory mantle cell lymphoma (MCL) in major clinical trials. Although there has been a dramatic improvement in survival outcomes in the salvage setting, nonresponders to ibrutinib have a bleak prognosis. Therefore, this retrospec...

Full description

Bibliographic Details
Main Authors: Young‐Woo Jeon, Seugyun Yoon, Gi June Min, Sung‐Soo Park, Silvia Park, Jae‐Ho Yoon, Sung‐Eun Lee, Byung‐Sik Cho, Ki‐Seong Eom, Yoo‐Jin Kim, Hee‐Je Kim, Seok Lee, Chang‐Ki Min, Jong Wook Lee, Seok‐Goo Cho
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Cancer Medicine
Subjects:
allogeneic stem transplantation
bendamustine
ibrutinib
mantle cell lymphoma
nonresponder
Online Access:https://doi.org/10.1002/cam4.2565

Internet

https://doi.org/10.1002/cam4.2565

Similar Items